Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-12-19, Stock:LLY, The news for the past five days is as follows:
2018-12-12: NEWS1: Lilly partners with AC Immune for Alzheimer's treatment.NEWS2: Lilly partners with AC Immune for Alzheimer's treatment.NEWS3: AC Immune and Lilly Announce License and Collaboration Agreement.NEWS4: Lilly and AC Immune Announce License and Collaboration Agreement.NEWS5: Lilly And AC Immune Enter Into License And Collaboration Agreement.NEWS6: Lilly And AC Immune Enter Into License And Collaboration Agreement.
2018-12-13: NEWS1: A Closer Look at Biogen’s Gross Margin Trends.NEWS2: Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Strong ETF Right Now?.NEWS3: Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Strong ETF Right Now?.NEWS4: Stocks - Ciena Jumps in Premarket, Apple Gains, Tailored Brands Crashes.NEWS5: Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug.NEWS6: Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug.NEWS7: Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Strong ETF Right Now?.NEWS8: Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug.NEWS9: See what the IHS Markit Score report has to say about Eli Lilly and Co..NEWS10: FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE).NEWS11: Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease.NEWS12: Eli Lilly : FDA Grants Fast Track Designation To Baricitinib Development Program.NEWS13: Eli Lilly : FDA Grants Fast Track Designation To Baricitinib Development Program.
2018-12-14: NEWS1: Lilly to Acquire Pre-Clinical Pain Program from Hydra Biosciences.NEWS2: Do Analysts See Any Upside for Ionis Stock?.NEWS3: Taking Stock of Ionis’s Performance.NEWS4: Understanding Ionis Pharmaceuticals’ Operational Performance.NEWS5: Mylan (MYL) Gets Favorable Ruling Against Sanofi's Lantus.NEWS6: Mylan (MYL) Gets Favorable Ruling Against Sanofi's Lantus.NEWS7: Mylan (MYL) Gets Favorable Ruling Against Sanofi's Lantus.NEWS8: Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?.NEWS9: Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?.NEWS10: Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus.NEWS11: Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus.NEWS12: 5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019.NEWS13: 5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019.NEWS14: Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?.NEWS15: Merck bolsters animal health unit with $2.4 bln Antelliq purchase.NEWS16: 5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019.NEWS17: Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus.NEWS18: Do Analysts See Any Upside for Biogen Stock?.NEWS19: Lilly and Evidation Health Expand Collaboration to Analyze Data from Smartphones and Connected Sensors.
2018-12-17: NEWS1: Incyte (INCY) Collaborates with Innovent for 3 Candidates.NEWS2: Incyte (INCY) Collaborates with Innovent for 3 Candidates.NEWS3: Merck to Acquire Europe's Antelliq Group for $2.4 Billion.NEWS4: Merck to Acquire Europe's Antelliq Group for $2.4 Billion.NEWS5: Merck to Acquire Europe's Antelliq Group for $2.4 Billion.NEWS6: Incyte (INCY) Collaborates with Innovent for 3 Candidates.NEWS7: 7 Major Pharmaceutical Stocks to Quarantine Now.NEWS8: Lilly (LLY) to Acquire Pain Candidate From Private Biotech.NEWS9: Lilly (LLY) to Acquire Pain Candidate From Private Biotech.NEWS10: J&J Dips 10% as Reuters Says Company Knew of Asbestos in Talc.NEWS11: J&J Dips 10% as Reuters Says Company Knew of Asbestos in Talc.NEWS12: Better Buy: Eli Lilly and Company vs. Merck & Co..NEWS13: Better Buy: Eli Lilly and Company vs. Merck & Co..NEWS14: Lilly (LLY) to Acquire Pain Candidate From Private Biotech.NEWS15: J&J Dips 10% as Reuters Says Company Knew of Asbestos in Talc.NEWS16: Better Buy: Eli Lilly and Company vs. Merck & Co..NEWS17: Dow Jones Futures: The Worst Part About This Stock Market Rally.NEWS18: Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial.NEWS19: Lilly Announces Positive Top-Line Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis.NEWS20: Eli Lilly: Taltz Meets Primary And Secondary Endpoints In Spirit-H2H Study.NEWS21: Eli Lilly: Taltz Meets Primary And Secondary Endpoints In Spirit-H2H Study.
2018-12-18: NEWS1: Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies.NEWS2: Teva Reports Positive Top-Line Data for Migraine Candidate.NEWS3: Teva Reports Positive Top-Line Data for Migraine Candidate.NEWS4: Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study.NEWS5: Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study.NEWS6: iShares Core High Dividend ETF Experiences Big Inflow.NEWS7: iShares Core High Dividend ETF Experiences Big Inflow.NEWS8: A Look At The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY).NEWS9: Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study.NEWS10: Teva Reports Positive Top-Line Data for Migraine Candidate.NEWS11: Health Care Sector Update for 12/18/2018: LXRX, LLY, APHB, JNJ, PFE, ABT, MRK, APHB.NEWS12: Health Care Sector Update for 12/18/2018: LXRX, LLY, APHB, JNJ, PFE, ABT, MRK, APHB.NEWS13: Lilly announces publication of analyses showing benefit of the addition of Verzenio® (abemaciclib) in multiple subgroups of patients with advanced breast cancer identified as having a more concerning prognosis.NEWS14: Darling Dozen - 12 Healthcare IPOs That Didn't Disappoint.NEWS15: Darling Dozen - 12 Healthcare IPOs That Didn't Disappoint.NEWS16: Elanco Initiates 2019 Guidance - Quick Facts.NEWS17: Elanco Initiates 2019 Guidance - Quick Facts.

Answer: Rise